Change of estrogen receptor, progesterone receptor, and Ki67 after neoadjuvant chemotherapy in patients with locally advanced breast cancer | ||||
Minia Journal of Medical Research | ||||
Article 35, Volume 30, Issue 4, October 2019, Page 217-225 PDF (394.87 K) | ||||
Document Type: Original Article | ||||
DOI: 10.21608/mjmr.2022.221719 | ||||
View on SCiNiTO | ||||
Authors | ||||
Nada H. Ali Sholkamy1; Wafaa M. Abd El-Latif2; Mohamed A. Hassan3; Amani S. Guirguis2; Marian F. Kamal4 | ||||
1Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicin, Minia University | ||||
2Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicin, Minia University. | ||||
3Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicin, Cairo University. | ||||
4Department of Pathology, Faculty of Medicin , Minia University | ||||
Abstract | ||||
Purpose: The aim of this study is aimed to demonstrate the changes in the estrogen receptor (ER), progesterone receptor (PR), Ki-67, after neoadjuvant chemotherapy in the patients with locally advanced breast cancer. Materials and Methods: seventy patients who diagnosed with locally advanced breast cancer and treated with neoadjuvant chemotherapy. Ki-67, ER, PR, tested by immunohistochemistry (IHC) was evaluated before and after neoadjuvant chemotherapy. Results: There was a statistically significant reduction in Ki-67, but no statistically significant reduction in ER, PR, after neoadjuvant chemotherapy. Conclusion: The significant change in the Ki-67 proliferation index may suggest the reduced proliferative activity of malignant cells with neoadjuvant chemotherapy. | ||||
Keywords | ||||
estrogen receptor; progesterone receptor; neoadjuvant chemotherapy | ||||
Supplementary Files
|
||||
Statistics Article View: 79 PDF Download: 140 |
||||